Par Committee seeks creation of separate drug controller for AYUSH medicines

New Delhi, Apr 5 : Par Committee seeks creation of separate drug controller for AYUSH medicines A parliamentary committee today sought creation of a separate drug controller for AYUSH medicines and drugs in a time-bound manner to ensure they are on a par with international standards.

The committee, which pointed out that market of Indian herbal drugs was declining worldwide, lamented the delay by the AYUSH ministry in fulfilling the assurance given on the issues of separate drug controller and legislations for education and practice of AYUSH systems of medicine.

According to the report submitted in the Lok Sabha today, the ministry had moved a proposal for setting up a separate drug controller for AYUSH medicines and it was put up for Cabinet approval.

However, upon a directive from PMO, the ministry decided to set up a vertical structure of AYUSH in the existing Central Drugs Standard Control Organization (CDSCO).

“Putting AYUSH drugs under the same structure of CDSCO as allopathic medicines is gross injustice towards AYUSH medicines and will not lead to fulfilment of the assurance which was give,” the report stated.

Since an inordinate length of time has been taken by the ministry without fulfilling the assurance, the committee directed the ministry to fulfil it in a time-bound manner and, meanwhile, also furnish a part implementation report detailing steps taken by it to ensure quality, safety, efficacy and standard of AYUSH drugs in the country.

The committee pointed out that two more assurances pertaining to the legislation for education and practice of AYUSH systems of medicine have been kept pending by the ministry for more than two years.

The committee expressed concern to note that there is no licensing authority for AYUSH medicines despite the fact that these are eternal medicinal practices.

It observed that absence of licensing authority for AYUSH medicines is the main reason for these medicines not getting the recognition they deserve in the country and abroad.

It also pointed out that there are no specific pharmacists for selling AYUSH medicines and no course has been prescribed for them as a result of which many countries have banned AYUSH medicines in their markets.

The committee also asked the Ministry of AYSUH to streamline the mechanism for implementation of eight assurances given by the government which are still pending.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India